ClinicalTrials.gg

Program

Safiglipron

Also written as “HRS-7535”, “HRS-7535 tablet” and “HRS-7535 Tablets”.

In Jiangsu HengRui Medicine's pipeline, GLP-1. Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Renal Insufficiency, Chronic · Diabetic Nephropathies, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Sep 6, 202419 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine193 open or runningphase 3since Sep 6, 2024Apr 20, 2022Dec 2026phase 2 · NCT06820099
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-7535, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Apr 20, 2022.

  1. May 14, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06422039 · 24 enrolled · China
  2. Jul 3, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06495931 · 24 enrolled · China
  3. Sep 6, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06589765 · 810 enrolled · China
  4. Sep 29, 2024Phase 2 study in OverweightNCT06621316 · 74 enrolled · China
  5. Oct 23, 2024Phase 2 study in Chronic Weight ManagementNCT06671821 · 81 enrolled · China
  6. Nov 1, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06672172 · 284 enrolled · China
  7. Dec 6, 2024Phase 1 study in Diabetes MellitusNCT06727838 · 18 enrolled · China
  8. Feb 5, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06819488 · 6 enrolled · China
  9. Feb 6, 2025Phase 2 study in ObesityNCT06820099 · 225 planned · China
  10. Mar 25, 2025Phase 3 study in OverweightNCT06904105 · 556 enrolled · China
  11. May 6, 2025Phase 1 study in Diabetes MellitusNCT06961643 · 24 enrolled · China
  12. Nov 26, 2025Phase 1 study in ObesityNCT07269756 · 40 enrolled · China
  13. Apr 7, 2026Phase 3 study in ObesityNCT07528027 · 648 planned · China
  14. May 29, 2026Phase 3 study in Renal Insufficiency, ChronicNCT07625774 · 3,690 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in ObesityNCT06820099
  2. Dec 2027Primary completion: phase 3 study in ObesityNCT07528027
  3. May 2031Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07625774

TargetBeta

“GLP-1”the company's pipeline, read by Claude · source

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
efpeglenatideruleHanmi Pharmaceuticalphase 313

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07625774Renal Insufficiency, Chronic · China3Not yet recruitingMay 20313,690
NCT07528027Obesity · China3RecruitingDec 2027648
NCT07269756Obesity · China1CompletedMar 8, 202640
NCT06961643Diabetes Mellitus · China1CompletedJan 22, 202624
NCT06904105Overweight · China3CompletedApr 17, 2026556
NCT06820099Obesity · China2RecruitingDec 2026225
NCT06819488Diabetes Mellitus, Type 2 · China1CompletedApr 16, 20256
NCT06727838Diabetes Mellitus · China1CompletedJan 25, 202518
NCT06672172Diabetes Mellitus, Type 2 · China3CompletedNov 13, 2025284
NCT06671821Chronic Weight Management · China2CompletedAug 15, 202581
NCT06621316Overweight · China2CompletedJul 14, 202574
NCT06589765Diabetes Mellitus, Type 2 · China3CompletedMay 29, 2026810
NCT06495931Diabetes Mellitus, Type 2 · China1CompletedAug 13, 202424
NCT06422039Diabetes Mellitus, Type 2 · China1CompletedAug 6, 202424
NCT06415214Diabetic Nephropathies · China2CompletedJul 15, 2025281
NCT06393348Diabetes Mellitus, Type 2 · China2CompletedNov 15, 2024155
NCT06132204Diabetes Mellitus, Type 2 · China1CompletedMar 13, 202416
NCT05759897Diabetes Mellitus, Type 22UNKNOWNDec 21, 2023180
NCT05347758Healthy Subjects1UNKNOWNSep 18, 2022106

How it is read

Names in the registry

  • “HRS-7535”, 7 entries
  • “HRS-7535 tablet”, 5 entries
  • “HRS-7535 Tablets”, 3 entries
  • “HRS-7535 tablets”, 2 entries
  • “HRS-7535 Tablet”, 1 entry

Codes read as this program: HRS7535.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.